{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:11:52Z","timestamp":1778739112485,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To systematically investigate the clinical characteristics and prognosis of patients with immune-mediated necrotizing myopathy (IMNM), and to explore the proteomic landscape associated with different clinical phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 133 IMNM patients were enrolled in this retrospective study. The clinical features and outcomes were compared across three subgroups: anti-HMGCR-positive, anti-SRP-positive, and seronegative patients. Unsupervised machine learning algorithms were applied to cluster patients independently of antibody status. Label-free data-independent acquisition quantitative proteomics was performed on samples from clustered IMNM patients and noninflammatory control subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No significant differences were observed in the overall prognosis among the three antibody-based subtypes. Unsupervised machine learning, independent of myositis-specific antibodies (MSA) status, identified three distinct phenotypes with unique clinical presentations and prognoses. Phenotype 1 (56.4%) corresponded to patients with muscle weakness and a more favorable prognosis. Phenotype 2 (10.5%) was characterized by the highest creatine kinase and lactate dehydrogenase levels, with an intermediate prognosis. Phenotype 3 (33.1%) was marked by a high incidence of ILD and a high mortality rate. Proteomic profiling revealed that these phenotypes exhibited distinct protein expression patterns and associated biological processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MSA are not effective for stratifying IMNM patients into subgroups that are more homogeneous with respect to ILD incidence and prognosis. Novel IMNM phenotypes identified independent of MSA status differ significantly in clinical outcomes and proteomic signatures, providing fresh insights into the pathogenic mechanisms underlying IMNM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1821033","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:34:40Z","timestamp":1778736880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel phenotypes of immune-mediated necrotizing myopathy identified independent of myositis-specific antibody specificity that improve prognostic stratification"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaojing","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]},{"name":"Center for Rare Diseases, The First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Electrophysiology, The First Affiliated Hospital of University of Science and Technology of China","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidan","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changpu","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liye","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Emergency, Changchun Hospital of Traditional Chinese Medicine","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]},{"name":"Center for Rare Diseases, The First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Affiliated Hospital of Jilin University","place":["Changchun, Jilin, China"]},{"name":"Center for Rare Diseases, The First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3233\/jnd-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x251314697","article-title":"Identification of clinical subgroups in anti-SRP positive immune-mediated necrotizing myopathy patients using cluster analysis","volume":"17","author":"Cui","year":"2025","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.03.032","article-title":"Cardiac and respiratory complications of necrotizing autoimmune myopathy","volume":"95","author":"Triplett","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1094611","article-title":"Characteristics of cardiac involvement in immune-mediated necrotizing myopathy","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.670784","article-title":"The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China","volume":"12","author":"Ma","year":"2021","journal-title":"Front Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.003","article-title":"Clinical and histological features of immune-mediated necrotising myopathy: a multi-centre South Australian cohort study","volume":"30","author":"Day","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52065","article-title":"CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM","volume":"11","author":"Sun","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae361","article-title":"Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical-serological-pathological classification","volume":"64","author":"Yang","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2401488","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5669","article-title":"Acute respiratory distress syndrome: the Berlin Definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004923","article-title":"Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103435","article-title":"Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"J Autoimmun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-020-01431-7","article-title":"Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies","volume":"15","author":"Zhao","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7962","article-title":"Anti-signal recognition particle antibody-associated severe interstitial lung disease requiring lung transplantation","volume":"12","author":"Qureshi","year":"2020","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac014","article-title":"Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101509","article-title":"Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis","volume":"33","author":"Bueno","year":"2020","journal-title":"Redox Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","article-title":"Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases","volume":"147","author":"Nelke","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2024.2370083","article-title":"Low serum complements in idiopathic inflammatory myositis: clinical features and impact on the prognosis","volume":"47","author":"Nomura","year":"2024","journal-title":"Immunol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.011","article-title":"Multiomics analysis uncovers subtype-specific mechanisms and biomarkers in idiopathic inflammatory myopathies","volume":"85","author":"Xiao","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/carj\/3183241","article-title":"Current understanding of pulmonary fibrosis: pathogenesis, diagnosis, and therapeutic approaches","volume":"2025","author":"Cui","year":"2025","journal-title":"Can Respir J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-010-0097-8","article-title":"TSP-1 in lung fibrosis","volume":"4","author":"Di Guglielmo","year":"2010","journal-title":"J Cell Commun Signal"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.04.022","article-title":"Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis","volume":"187","author":"Salajegheh","year":"2007","journal-title":"J Neuroimmunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.6_suppl.286s","article-title":"The myofibroblast in pulmonary fibrosis","volume":"122","author":"Phan","year":"2002","journal-title":"Chest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:34:42Z","timestamp":1778736882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1821033"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1821033","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1821033"}}